{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-007003","form_type":"8-K","ticker":"ANIK","cik":"0000898437","company_name":"Anika Therapeutics, Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.542378+00:00","generated_at":"2026-05-17T00:29:51.970096+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Anika Q3 revenue down 6% to $27.8M; files final Hyalofast PMA with mixed Phase III data","bullets":["Q3 continuing ops rev $27.8M (-6% YoY); loss per share ($0.22); adj EPS $0.04; adj EBITDA $0.9M.","Commercial Channel rev up 22% YoY; Integrity procedures on track to double in 2025; J&J extends Monovisc license to 2031.","Commencing $15M share repurchase via 10b5-1 plan expected to complete by June 2026.","Filed final Hyalofast PMA module; Phase III trial missed primary endpoints but showed significant secondary endpoint benefits.","Hyalofast used in >35K patients globally; Breakthrough Device Designation; post-hoc analyses showed statistical significance in KOOS Pain."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-007003","json":"https://secwatch.observer/filing/0001171843-25-007003.json","markdown":"https://secwatch.observer/filing/0001171843-25-007003.md","text":"https://secwatch.observer/filing/0001171843-25-007003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/898437/000117184325007003/0001171843-25-007003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/898437/000117184325007003/f8k_110525.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:29:51.970096+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}